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Abstract
C57BL/6 mice are the most widely used strain of laboratory mice. Using in vivo proton Magnetic Resonance Spectroscopy
(1H MRS), we have repeatedly observed an abnormal neurochemical profile in the brains of both wild-type and genetically
modified mice derived from the C57BL/6J strain, consisting of a several fold increase in cerebral glutamine and two fold
decrease in myo-inositol. This strikingly abnormal neurochemical ‘‘phenotype’’ resembles that observed in chronic liver
disease or portosystemic shunting and appeared to be independent of transgene, origin or chow and was not associated
with liver failure. As many as 25% of animals displayed the abnormal neurochemical profile, questioning the reliability of this
model for neurobiology. We conducted an independent study to determine if this neurochemical profile was associated
with portosystemic shunting. Our results showed that 100% of the mice with high brain glutamine displayed portosystemic
shunting by concomitant portal angiography while all mice with normal brain glutamine did not. Since portosystemic
shunting is known to cause alterations in gene expression in many organs including the brain, we conclude that
portosystemic shunting may be the most significant problem associated with C57BL/6J inbreeding both for its effect on the
central nervous system and for its systemic repercussions.
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Introduction
In the last three decades, mouse models have contributed to
enormous advances in characterizing the molecular underpinnings
of disease through the use of transgenesis and other approaches.
The C57BL/6 strain is one of the most widely used for both
transgenesis and environmental exposure experiments [1,2,3,4,5].
Low tumor incidence is one of its many advantages, unlike the
high frequency in early mouse-based experiments (http://www.
informatics.jax.org, http://www.harlan.com). However, several
phenotypes (e.g. microphtalmia, hydrocephalus, and other gene-
based anomalies) suggestive of inbreeding have been reported
[6,7].
Our facility (CIBM) is a regional imaging center for in vivo
proton Magnetic Resonance Spectroscopy (1H MRS) and Imaging
(MRI). As such, we routinely perform in vivo 1H MRS measure-
ments on more than one thousand wild-type and transgenic
animals originating from different laboratories and suppliers. Since
establishing the CIBM (Centre d’Imagerie Biomedicale) in 2005,
we have repetitively observed an abnormal neurochemical pattern
consisting of increased cerebral glutamine (Gln) concentration and
decreased myo-inositol (Ins) concentration in the brains of both
wild-type and genetically modified mice, all of which were derived
from the C57BL/6J strain. Gln and Ins were the only substantial
changes in the neurochemical profile, consisting of 20 brain
metabolites. This neurochemical ‘‘phenotype’’ was reminiscent of
what has been described in patients with chronic liver disease
[8,9,10]. The findings appeared to have a high incidence and to be
independent of transgene, origin, chow, and type of experiment.
1H MRS spectra displaying high Gln and low Ins are typically
attributed to liver failure or to portosystemic (PS) shunting
[8,9,10,11,12,13,14,15]. In the absence of any sign of liver failure,
we hypothesized that the mice with elevated cerebral Gln
measured in vivo by 1H MRS would have portosystemic shunts,
a congenital anomaly well described in other mammalian species
[16,17,18,19]. Therefore, the aim of the present study was to
determine if the C57BL/6J mice with the observed abnormal
neurochemical profile showed evidence of portosystemic shunting.
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Materials and Methods
Animals
All animal experiments were conducted according to federal
and local ethical guidelines, and the protocols were approved by
the local regulatory body of the Canton Vaud, Switzerland
(EXPANIM (Expe´rience sur animaux) – SCAV, De´partement de
la se´curite´ et de l’environnement, Service de la consommation et
des affaires ve´te´rinaires).
All our animals (wild-type and genetically modified) were
provided by official suppliers or different academic or commercial
animal facilities nationwide. For the purpose of the present study
we are presenting only some of the ‘‘High Gln’’ mice identified in
our laboratory (total of n= 23 mice). All the mice were C57BL/6J
or back-crossed with this strain.
1H MRS Measurements
In vivo serial proton localized spectra were measured during post
natal day (P) 10, 20, 30, 60, 90 to control for any developmental
effect. Measurements were performed in the cortex of ‘‘Normal
Gln’’ mice n= 11 and ‘‘High Gln’’ mice n= 11 (6 females and 5
males) (volume of interest (VOI) of 0.86461.2 mm3,) at all
developmental time points. In adult animals aged 4 (n= 12, 7
males) and 12 months (n = 7, 5 males), the striatum (VOI of
26262 mm3), hippocampus (VOI of 1.261.662.2 mm3) and
cortex (VOI of 0.86461.2 mm3) were measured individually.
Anesthesia was maintained for the length of the procedure using
1.360.2% of isoflurane in oxygen. Body temperature was
measured with a rectal thermosensor and maintained at
36.560.5uC by warm water circulation. Respiration rate was
monitored by a small-animal monitor system (SA Instruments Inc.,
New York, NY, USA). All data were acquired on a 14.1T/26 cm
system (Varian/Magnex Scientific) using a home-built
14 mm621 mm quadrature coil as RF transceiver and an ultra-
short-echo time SPECIAL spectroscopy sequence (echo time
(TE) = 2.8 ms, repetition time (TR) = 4 s, 400 scans) [20]. The
static field was shimmed by FASTMAP [21]. After first and second
order shimming, the typical linewidth of water resonance at
TE= 2.8 ms was 18–23 Hz.
Metabolite concentrations were estimated using LCModel
(http://s-provencher.com), combined with a simulated basis-set
of metabolites and the spectrum of macromolecules measured
in vivo [22,23]. Absolute metabolite concentrations were obtained
using unsuppressed water signal as a reference. The Crame´r-Rao
lower bounds (CRBs)) were calculated by LCModel as a measure
of the reliability of the metabolite estimates. Using in vivo 1H
MRS at ultra-short echo time we were able to reliable quantify 20
brain metabolites, with CRBs below 20%, involved in: myelina-
tion/cell proliferation (phosphocholine (PCho), glycerophospho-
choline (GPC), phosphoethanolamine (PE), N-acetylaspartate
(NAA), N-acetylaspartylglutamate (NAAG)), energy metabolism
(glucose (Glc), lactate (Lac), creatine [5], phosphocreatine (PCr),
alanine (Ala)), osmoregulation (taurine (Tau), myo-inositol (Ins)),
neurotransmitter metabolism (glutamate (Glu), glutamine (Gln),
aspartate (Asp), c-aminobutyrate (GABA), glycine (Gly)) and
antioxidants (ascorbate (Asc), glutathione (GSH)).
Blood Measurements
Plasma ammonia and glutamine concentrations were measured
from all animals using an Analox GM7 analyzer (Analox
Instruments, London, UK) as previous published [24]. Assessment
of liver function was performed by measuring plasma aspartate
amino transferase (AST), alanine amino transferase (ALT) and
total bilirubin using a Reflotron Plus analyzer (Roche Diagnostics
GmbH, Mannhein, Germany). AST was considered normal when
ranging between 54 to 298 (U/I), ALT when ranging between 38
to 106 (U/l), and bilirubin when ,0.5 mg/dl (http://www.lar.
iastate.edu, www.medical-solution.ch – Reflotron manual).
Breeding
One high glutamine (Gln) female and male was used to obtain
two litters of offspring. All offspring (n = 9) were furthermore
subject to only in vivo 1H MRS measurements as previously
described.
Portal Angiography
Five ‘‘High Gln’’ (n = 3 at 4 months and n= 2 at 12 months,
males) and five ‘‘Normal Gln’’ (n = 3 at 4 months, males and n= 2
at 12 months, females) mice underwent 1H MRS measurements
prior to portal angiography, to confirm the abnormal neurochem-
ical pattern. Mice were anesthetized using isoflurane (3% for
induction and 2% thereafter, 1L/min O2 flow). Following a
midline incision, the mesentery was overturned to the left side of
the abdomen in order to best expose the inferior mesenteric vein.
The vein was isolated and encircled with two 7–0 silk ties, then a
heparin-flushed 26-French catheter was introduced into the vein
and secured with the silks. The tip of the catheter was placed
between the gastro-splenic and the duodeno-pancreatic veins.
Portal angiographies were performed on a digital subtraction
angiography system equipped with a 406 48 cm flat panel
detector (Allura Xper FD 20; Philips Medical System, Best The
Netherlands). The mice were placed in the supine position on the
angiography table. The 26-F catheter in the portal vein was
attached through a 26-F connecting tube to an infusion pump
(Module DPS Orchestra; Frenesius Vial, Brezins, France).
Standard postero-anterior angiograms were obtained during
continuous injection of iodinated contrast media (350 mg
iodine/ml of iohexol, Accupaque; GE Healthcare, Oepfikon,
Switzerland), Cork, Ireland) with the following image parameters:
tube voltage, 120 kV; modulated tube current; inherent filtration,
2.7 mm aluminium; pulse width, 6 ms; system dose, 0.36 mGy per
pulse; focal spot, 0.7 mm; tube detector distance, 0.4 m; matrix
size, 102461024; zoom factor, 5x; field of view, 764 cm;
acquisition time, 15 s; delay time, 2 s. Then, a 3D rotational
computed tomography (CT) was acquired with the following
parameters: a total acquisition angle of 222u, projection increment
of 0.8u. The CT images were reconstructed and analyzed on a
dedicated workstation (Xper CT; Philips Medical System, Best
The Netherlands). In order to optimize contrast media injection,
we performed successive portal angiographies with different flow
rate (75 mL/h; 150 mL/h; 300 mL/h; 600 mL/h) on two test
animals. The optimal flow rate of 150 mL/h (corresponding to
0.042 mL/s) was used in the ‘‘Normal Gln’’ group (n= 5) and in
the ‘‘High Gln’’ group (n= 5).
Histology
Livers were harvested following portal angiography (n= 5 for
‘‘High Gln’’ mice and n= 5 for ‘‘Normal Gln’’ mice). To control
for injection artifacts (i.e. modifications of the liver parenchyma
restricted to the lobules, which did not impact assessment of portal
tract and centrilobular vein), we also harvested livers from two 4
months old ‘‘High Gln’’ female mice and two 4 months old
‘‘Normal Gln’’ female mice (previously confirmed by 1H MRS)
having not undergone portal angiography.
All tissues were fixed in 10% buffered formalin overnight at
room temperature, then paraffin-embedded. For routine histolog-
ical examination, 3 mm-thick sections were stained with haema-
toxylin-eosin (H&E), Masson’s trichrome, and a reticulin stain.
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Immunohistochemistry was performed on paraffin-embedded
sections mounted on positively charged slides, using an automated
DAKO immunostainer (DakoCytomation, Glostrup, Denmark).
The following primary antibodies were applied: CD31 (PECAM-
1, M-20, sc-1506, goat polyclonal, Santa Cruz Biotechnology,
Inc., Heidelberg, Germany), and D2–40 (Podoplanin, goat
polyclonal, R&D Systems, Abingdon, UK). First, for antigen
retrieval, deparaffinized and rehydrated sections were treated
using an electric pressure cooker for CD31 (Pascal Tris EDTA
buffer, pH7.0, for 30 seconds) and a microwave for D2–40 (citrate
buffer, pH6.0, for 10 minutes). Then the sections were mounted in
the DAKO autostainer, covered with blocking peroxidase for 5
minutes. Slides were incubated for 60 minutes with the diluted
antibody (CD31 1:200; D2–40 1:1000). This step was followed by
applying the labelled rabbit anti-goat HRP method (DAKO; 1:20,
30 minutes). DAB (DAKO) was used as a chromogen.
Apart from routine liver architecture, portal tract, centrilobular
vein, and hepatocyte evaluation, the following were also assessed:
relative sizes of portal veins and lymphatics, total numbers of
portal tracts and lymphatic vessels, and mean lymphatic profiles
per portal tracts.
Statistical Analyses
All the results are presented as mean 6 SD of n mice, unless
otherwise indicated. A two-way ANOVA followed by the
Bonferroni’s multi-comparison post-test was used to compare the
concentration of neurochemicals. ANOVA during development
was performed for each neurochemical in 2 groups65 time points
(ages from P10 to P90), whereas in adult mice was performed for
each neurochemical at each age in 2 groups63 brain areas.
Statistical analyses were performed using Prism 5.03 (GraphPad,
La Jolla CA USA).
Results
The ultra-short echo time sequence combined with the
availability of ultra-high magnetic field (14.1T) yielded 1H spectra
with excellent signal-to-noise ratio (SNR) and with a clear
separation of the Gln and glutamate (Glu) peaks (Figure 1). In
adult mice the Gln concentration was considered to be normal
when ranging between 2.7–3.8 mmol/g, as previously described
[25,26] and illustrated in Figures 1 and 2. Additionally, adult
‘‘High Gln’’ mice displayed Gln concentrations ranging from 5.5
to 12 mmol/g.
To determine whether the neurochemical changes in Gln and
Ins could be ascribed to developmental fluctuations, we performed
serial in vivo 1H MRS measurements in the cortex of developing
mice from post-natal day (P) 10 to P90 (Figure 2A). In brief, our
findings show that cerebral Gln concentrations rise very early in
the ‘‘High Gln’’ pup, reaching a plateau in the adult. A 20%
increase in Gln concentration was noticeable as early as P10,
reaching a 50% increase at P20 (p,0.01) in the ‘‘High Gln’’ mice
compared to age-matched animals coming from the same supplier.
At P30 the ‘‘High Gln’’ mice showed a ,3 fold elevation of
cerebral Gln compared to control mice (10.061.7 mmol/g for
‘‘High Gln’’ mice and 3.160.3 mmol/g for ‘‘Normal Gln’’ mice,
p,0.001) with no further increase at P90. Likewise, a 28%
decrease in Ins was observed in the pup at P10, continuing further
until P90 (i.e. 50% decrease at P30, p,0.001) in ‘‘High Gln’’ mice.
Ins concentration remained constant thereafter, in keeping with
Gln findings. Taurine, another important brain osmolyte, is the
only other metabolite which displayed variation, also showing
variation from the norm in the very small pups (25% decrease) in
‘‘High Gln’’ mice, which reached significance at P10 and P90
(p,0.05). No statistically significant modifications in the concen-
tration of other brain metabolites were observed (Figure 2A).
To determine whether the increase of Gln was region specific,
we performed in vivo neurochemical profile assessments of the
striatum, hippocampus and cortex in 4- and 12-month old mice
(Figure 2B). High Gln (significant 3 fold increase compared to
controls, p,0.001) and low Ins concentrations (significant 30%
decrease) were apparent in all brain regions investigated at 4 and
12 months of age in the ‘‘High Gln’’ mice. The abnormal
neurochemical pattern observed in cortex, striatum and hippo-
campus of ‘‘High Gln’’ adult mice was similar to the results
obtained during brain development. The other metabolites did not
show any significant temporal or spatial fluctuations, except for a
small decrease of other brain osmolytes, i.e. Tau (20%) in the
striatum and tCr (10%) in the cortex of ‘‘High Gln‘‘ mice at 12
months of age.
To determine the presence of a systemic phenotype, we
performed serial weight and biochemical measurements. There
was no significant difference in mean weight between the ‘‘High
Gln’’ and ‘‘Normal Gln’’ mice at any time point: ‘‘High Gln’’ at 4
months weighed 3063 g and ‘‘Normal Gln’’ weighed 2963 g. No
statistical differences were observed for plasma ammonia
(270640 mM for ‘‘High Gln’’ mice and 270660 mM for ‘‘Normal
Gln’’ mice, p= 0.9) and plasma glutamine concentrations
(0.9060.06 mM for ‘‘High Gln’’ mice and 0.8860.12 mM for
‘‘Normal Gln’’ mice, p= 0.8). As the aforementioned changes are
a hallmark of hepatic encephalopathy in humans
[8,9,10,11,12,13], we assessed liver function in ‘‘High Gln’’ and
‘‘Normal Gln’’ mice. Total bilirubin, aspartate amino transferase
(AST) and alanine amino transferase (ALT) were within normal
Figure 1. Representative in vivo spectra acquired at 14.1T in
the cortex (VOI = 0.86461.2 mm3) of ‘‘High Gln’’ (A) and
‘‘Normal Gln’’ (B) C57BL/6J mice. The increase of Gln and decrease
of Ins in the cortex of the ‘‘High Gln’’ mouse is visually apparent. Only
those metabolites displaying a concentration change are labeled (i.e.
Gln and Ins) for the ‘‘High Gln’’ spectrum.
doi:10.1371/journal.pone.0069782.g001
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limits for all animals (total bilirubin was below 0.5 mg/dl for all
investigated animals). AST and ALT remained within the normal
range but displayed a higher variability in the ‘‘High Gln’’ mice
(AST: 2726169 U/l and ALT: 82656 U/l) compared to
‘‘Normal Gln’’ mice (AST: 102652 U/l and ALT: 2266 U/l)
(p = 0.1 for both AST and ALT).
To characterize the heritability pattern of this trait, a ‘‘High
Gln’’ male and ‘‘High Gln’’ female were crossed, yielding two
litters (n = 9). None of the pups showed the characteristic
abnormal neurochemical profile (data not shown) by 1H MRS,
and therefore no further measurements were performed on these
animals.
To assess the presence of portosystemic shunts, portal angio-
grams were obtained in all animals (Figure 3), after performing 1H
MRS measurements to confirm the abnormal neurochemical
pattern. The portal vein was patent in all animals, with
hepatopetal flow and a mean diameter of 1.360.2 mm (1.1–
1.6 mm). There were no angiographic signs of portal hyperten-
sion. In ‘‘Normal Gln’’ mice, contrast media flowed from the
portal vein immediately into the portal branches of the liver
(Figure 3B). After the parenchymal phase, the contrast entered the
suprahepatic inferior vena cava with a small retrograde filling of
the intrahepatic inferior vena cava. Conversely, in ‘‘High Gln’’
mice, the contrast medium flowed from the portal vein directly
into the suprahepatic inferior vena cava, without enhancement of
the intrahepatic portal veins or the liver parenchyma (Figure 3A).
The CT images indicated a shunt between the portal vein and the
inferior vena cava in all cases (n = 5). The shunt was visible as a
short segment that ran perpendicular to both the portal vein and
inferior vena cava within the left side of the liver, consistent with a
patent ductus venosus. Mean shunt length was 1.660.4 mm (1.2–
2.2 mm). In two animals of this group, we also detected an early
enhancement of the left atrium, suggestive of an atrial septal
defect.
PS shunts are associated with subtly abnormal liver histology
[19,27]. Portal vein branch hypoplasia is the most characteristic
finding [19,27]. We therefore assayed the histology of ‘‘Normal
Gln’’ mice (n = 5 after angiography and n=2 without angiogra-
phy) and ‘‘High Gln’’ mice (n = 5 after angiography and n= 2
without angiography). No architectural remodeling, or portal tract
fibrosis were observed. Lobular organization and hepatocyte
structure were normal in appearance. Portal vein anomalies were
observed exclusively in the ‘‘High Gln’’ mice. They consisted of
small, hypoplastic or absent portal veins in portal tracts, in
association with frequent inlet veinule dilatation. Portal vein
anomalies were seen in all ‘‘High Gln’’ mice, in 36% to 80% of
portal tracts (80% [16/20]; 44.4% [16/36]; 36% [18/50]; 42.5%
[34/80]; 44.8% [26/58]). Medium-sized portal tracts were mostly
affected, whereas control mice showed large intrahepatic portal
veins in all assessed portal tracts. Further, lymphatic channel
ectasia was observed and confirmed after D2–40 immunohisto-
Figure 2. In vivo 1H MRS results obtained in the brain of ‘‘High
Gln’’ and ‘‘Normal Gln’’ C57BL/6J mice. A) Evolution of brain
metabolite concentrations during mouse development at P 10, 20, 30,
60 and 90; open squares indicate ‘‘Normal Gln’’ mice and triangles
indicate ‘‘High Gln’’ mice; and B) metabolite concentrations in the
striatum (str), hippocampus (hip) and cortex (ctx) of ‘‘High Gln’’ and
‘‘Normal Gln’’ C57BL/6 mice at 4 and 12 months of age. Two-way
ANOVA was performed at 5 developmental time-points (ages P10 to
P90) comparing the ‘‘High Gln’’ mice to ‘‘Normal Gln’’ mice for each
metabolite. Statistically significant differences for Gln, Tau and Ins
between ‘‘High Gln’’ and ‘‘Normal Gln’’ mice (df = 1, F value between
23.6 and 625) are marked *(p,0.05), **(p,0.01) and ***(p,0.001). The
age comparison showed statistical differences for all plotted metabo-
lites (p,0.0001, df = 4, F value between 19.2 and 139) (not shown). We
observed statistically significant age-dependent differences between
groups for Ins and Gln (p = 0.002 and p,0.0001 respectively, df = 4, F
value 4.47 and 66.7, respectively) (not shown). In adult mice two-way
ANOVA was performed for each neurochemical at each age (4 and 12
months) in 2 groups (‘‘High Gln’’ vs ‘‘Normal Gln’’ mice)63 brain areas.
Statistically significant differences for Gln, Glu, Tau, Ins and tCr between
‘‘High Gln’’ and ‘‘Normal Gln’’ mice (df = 1, F value between 14 and 519)
are marked *(p,0.05), **(p,0.01) and ***(p,0.001). Additionally, the
brain regions comparison showed statistical differences for some of the
plotted metabolites (Glu, NAA, Tau, Ins p,0.001, df = 2, F value
between 10 and 87) (not shown). Lac: lactate, GABA: c-aminobutyrate,
NAAG: N-acetylaspartylglutamate, NAA: N-acetylaspartate, Gln: gluta-
mine, Glu: glutamate, Asp: aspartate, Cr: creatine, PCr: phosphocreatine,
PE: phosphoethanolamine, PCho: phosphocholine, GPC: glyceropho-
sphocholine, Tau: taurine, Ins: myo-inositol, Gly: glycine, GSH: glutathi-
one, Asc: ascorbate.
doi:10.1371/journal.pone.0069782.g002
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chemistry (Figure 4). It was more prominent in the ‘‘High Gln’’
mice, but was also observed in the controls. Mean lymphatic
profile count per portal tracts did not differ significantly (‘‘High
Gln’’ mice: 1.81 to 4.3 lymphatic profiles/portal tract; controls:
1.5 to 2.44) (p = 0.097). Centrilobular veins were unaffected in
both ‘‘High Gln’’ and ‘‘Normal Gln’’ animals.
Discussion
This study shows that a high fraction of C57BL/6J mice present
an abnormal neurochemical profile consisting of elevated cerebral
Gln concentrations and decreased cerebral Ins (‘‘High Gln’’ mice),
and that these changes are associated with the presence of
congenital portosystemic shunts.
To the best of our knowledge, this is the first report describing
an abnormal neurochemical profile identified using in vivo 1H
MRS in a large proportion of wild-type and genetically modified
C57BL/6J mice. However, the incidence of this profile was
variable. Findings were independent of transgene, type of
investigation, chow or origin.
Note the excellent agreement with previous studies of regional
and developmental changes (Figure 2) in the murine neurochem-
ical profile [25,26]. For example, NAA concentration in the cortex
of adult ‘‘Normal Gln’’ mice was 8.660.7 mmol/g in perfect
agreement with the value of ,8.5 mmol/g previously reported
[25,26].
The abnormal neurochemical profile consisted of increased
cerebral Gln concentration by an average of 3 fold and 50%
decreased cerebral Ins affecting all brain regions. It has to be
emphasized that a 3 fold increase in Gln is well in excess of any
change considered statistically significant in a given mouse for all
of the studies performed at our center.
Therefore, this unique phenotype is far from a variation of the
norm. This characteristic profile is typical of hepatic encephalop-
athy associated with chronic liver disease and portosystemic
shunting [8,9,10,11,12,13,15]. Here, we show that 100% of ‘‘High
Gln’’ animals subjected to portal angiography displayed intrahe-
patic portosystemic shunts, in contrast to the ‘‘Normal Gln’’ mice.
Liver histology revealed hypoplastic portal branch segments
consistent with descriptions in dogs and humans [19,27].
The commonly accepted pathophysiology of central nervous
changes in liver disease and portosystemic shunting is that portal
blood bypasses the liver, thereby reaching the systemic circulation
without undergoing the necessary transformation in the liver.
Thus, exogenous and endogenous substances such as ammonia
enter the systemic circulation directly. In the central nervous
system, ammonia is detoxified into Gln via the astrocyte-specific
enzyme glutamine synthethase [15,24,28,29]. The end-result of
CNS ammonia detoxification is elevated Gln concentration in
astrocytes and efflux of other osmolytes [8,9,10,11,12,13,14,15].
We therefore conclude that the abnormal neurochemical profile
detected in the C57BL/6J mice is most likely due to portosystemic
shunting-induced CNS ammonia detoxification. The associated
decrease in Ins and other osmolytes is consistent with osmoreg-
ulation [8,9,10,11,12,13,14,15]. In the present study, there was a
noticeable decrease of other brain osmolytes (Tau and tCr) in
older animals, suggestive of ongoing osmoregulation and consis-
tent with published findings in models of chronic liver disease and
in patients [8,9,10,15].
High cerebral Gln concentration is detectable in vivo only by 1H
MRS. No, biochemical or physical measurements performed
allowed to distinguish ‘‘High Gln’’ from the ‘‘Normal Gln’’ mice.
This raises the important question of how to screen for this defect.
At present, we are not aware of an affordable and practical
alternative to in vivo 1H MRS scanning. Plasma ammonia does not
seem to be sensitive enough since this measurement was within the
normal range for most of our animals, also observed in dogs and
humans [19,30,31].
Congenital PS shunts are characterized by similar pathophys-
iology and histology, whether intra- or extrahepatic. The shunts
identified in our animals resemble incomplete ductus venosus (DV)
closure, typical for intrahepatic shunts [32]. Congenital PS shunts
Figure 3. Representative angiographies obtained in a ‘‘High Gln’’ mouse (A) and in a ‘‘Normal Gln’’ (B) C57BL/6J mouse. Normal
filling of the portal tree is visible in B. In A, injection in the superior mesenteric vein leads to immediate filling of the inferior vena cava. Inferior vena
cava (IVC), portal vein (PV), shunt (Sh).
doi:10.1371/journal.pone.0069782.g003
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have been described in other mammals (cats, dogs) and humans
[16,17,18,19,27,32]. However, the cause of this developmental
defect remains unclear: in Irish wolfhounds, patency of the DV
appears to be a digenic trait [19], while in Cairn terriers non-
closure of the DV appears to follow a more complex mode of
inheritance [19]. The serendipitous finding that in the Ahr2/2
mouse model (aryl hydrocarbon receptor deficient mice), all null
animals show patency of the DV [33] has put forward the Ahr-
ARNT-CYP1 signaling cascade as a possible candidate in
embryonic vascular remodeling. However, there are two reasons
why this gene is unlikely to be the sole culprit in the C57BL/6J
mouse: a) the inheritance pattern differs and b) the Ahr2/2
mouse displays a number of other vascular anomalies [33] not
present in the C57BL/6 mouse. In our study offspring of ‘‘High
Gln’’ parents did not show any neurochemical anomalies,
suggesting a non-mendelian inheritance pattern. Furthermore,
environmental influences appear to be unlikely as the defect was
identified in a large number of wild-type and transgenic animals
hosted in more than 5 animal facilities. Epigenetic modifications
are currently accepted to be at the root of seemingly erratic
inheritance patterns [34,35,36], something we aim to address in
further studies. Finally, no other strain of mice investigated in our
center to date displayed such a neurochemical profile. In the last 7
years we have performed 1H MRS in more than one thousand
mice originating from at least 7 different mice strains (including
NMRI, BALB/c, ICR CD1, NUDE, NOD-SCID, SV 129,
C57BL/6). Therefore, we propose that akin to what is seen in
purebred dogs, inheritance of intrahepatic PS shunt is complex,
and possibly limited to the C57BL/6 strain, the most commonly
used strain of laboratory mice.
It is interesting to note that the same abnormal neurochemical
profile identified using in vivo 1H MRS (increased brain Gln and
decreased brain Ins) was reported in a significant proportion of
wild-type and genetically modified C57BL/6 mice in a study of a
mouse model of Huntington’s disease [37], although the under-
lying cause was not identified.
Figure 4. Representative immunohistochemistry findings in a ‘‘High Gln’’ mouse (A, B) and in a ‘‘Normal Gln’’ mouse (C, D). Original
magnification 100x. A and C: CD31 immunostaining highlights endothelial cells. In the ‘‘High Gln’’ mouse (A), the hepatic artery branch is of normal
size, similar to that of the interlobular bile duct; the portal vein is small and hypoplastic, and the inlet venules are dilated. In the ‘‘Normal Gln’’ mouse
(C), the portal vein is large, with a normal size ratio to the interlobular bile duct (the hepatic artery branch is not seen in this section). The inlet venule
is thin. B and D: D2–40 expression confirms the lymphatic nature of the dilated channels at the periphery of the portal tracts in the ‘‘High Gln’’ mouse
(B), being selectively reactive in lymphatic endothelial cells, contrary to arterial and venous endothelial cells. Of note, D2–40 (podoplanin) reactivity is
also seen in bile duct epithelium. Abbreviations: A = hepatic artery; B = interlobular bile duct; CLV= centrilobular vein; IV = inlet venule; L = lymphatic
vessel; V = portal vein.
doi:10.1371/journal.pone.0069782.g004
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We observed that as many as 25% (or even higher) of C57BL/
6J animals enrolled in a given study conducted in our facility
displayed an abnormal neurochemical profile in all regions of the
brain, and that this finding existed in animals with congenital PS
shunts. The frequency of this characteristic neurochemical profile,
typically attributed to PS shunting or chronic liver disease, raises
the question of the reliability of this model for neurobiology in the
absence of appropriate tools to screen the animals.
The implications of the current findings are likely far-reaching:
in humans, PS shunting is associated with many systemic changes,
namely cardiac, renal, hepatic and pulmonary [32]. First, it has
recently been shown in PS shunting that the expression of a variety
of genes is altered in the central nervous system including that of
neurotransmitter receptors, transporters and members of second-
ary messenger signal transduction [38]. PS shunting has also been
shown to display significant abnormalities in the biology of
inflammation [39]. Second, there is ample evidence of altered
gene expression in other organs in PS shunting, such as: skeletal
muscle, pancreas, peripheral tissues and liver
[38,40,41,42,43,44,45,46].
We conclude that, although congenital anomalies associated
with the inbreeding of C57BL/6 have already been identified
(ocular defects, genetic polymorphisms among substrains, behav-
ioral differences among substrains [1,2,3,4,5,6,7]), PS shunting
may well be the most significant. Using 1H MRS of mouse brain
or an appropriate, as of yet unknown, other screening method may
allow to screen for PS shunted animals, and thus to control for the
systemic effects of PS shunting in studies based on the C57BL/6
strain and possibly derived strains.
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